

## PE anti-mouse Ly-6G Antibody

<b>Catalog# / Size</b>	127607 / 50 µg 127608 / 200 µg
<b>Clone</b>	1A8
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Lymphocyte antigen 6 complex, locus G
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Ly-6G transfected EL-4J cell line.
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C.
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	<p>While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C<sup>15</sup>. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8<sup>15</sup>. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4<sup>16</sup>.</p> <p>Additional reported applications (for the relevant formats) include: immunohistochemistry<sup>9</sup> of frozen sections<sup>10</sup> and paraffin-embedded sections<sup>11</sup>, depletion<sup>4, 12-14</sup>, and spatial biology (IBEX)<sup>20,21</sup>. The Ultra-LEAF™ purified antibody (Endotoxin &lt; 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for <i>in vivo</i> studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).</p>
<b>Application References</b>	<ol style="list-style-type: none"> <li>Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2399. (FC)</li> <li>Daley JM, <i>et al.</i> 2008. <i>J. Leukocyte Biol.</i> 83:1. (FC)</li> <li>Dietlin TA, <i>et al.</i> 2007. <i>J. Leukocyte Biol.</i> 81:1205. (FC)</li> <li>Daley J, <i>et al.</i> 2007. <i>J. Leukocyte Biol.</i> doi:10.1189. (Deplete) <a href="#">PubMed</a></li> <li>Tadagavadi RK, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:4904. <a href="#">PubMed</a></li> <li>Sumagin R, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:7057. <a href="#">PubMed</a></li> <li>Guiducci C, <i>et al.</i> 2010. <i>J. Exp Med.</i> 207:2931. <a href="#">PubMed</a></li> <li>Fujita M, <i>et al.</i> 2011. <i>Cancer Res.</i> 71:2664. <a href="#">PubMed</a></li> <li>Van Leeuwen, <i>et al.</i> 2008. <i>Arterioscler. Thromb. Vasc. Biol.</i> 28:84. (IHC)</li> <li>Kowanetz M, <i>et al.</i> 2010. <i>P. Natl. Acad. Sci. USA</i> 107:21248. [supplementary data] (IHC)</li> <li>Esbona K, <i>et al.</i> 2016. <i>Breast Cancer Res.</i> 18:35. (IHC)</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

12. Wojtasiak M, *et al.* 2010. *J. Gen. Virol.* 91:2158. (FC, Deplete)
13. Jaeger BN, *et al.* 2012. *J. Exp. Med.* 209:565. (Deplete)
14. Wozniak KL, *et al.* 2012. *BMC Immunol.* 13:65 (FC, Deplete)
15. Ribechini E, *et al.* 2009. *Eur. J. Immunol.* 39:3538.
16. Ng LG, *et al.* 2011. *J Invest. Dermatol.* 131:2058. [PubMed](#)
17. Ma C, *et al.* 2012. *J. Leukoc. Biol.* 92:1199.
18. McCartney-Francis, N, *et al.* 2014. *J Leukoc. Biol.* 96:917. [PubMed](#)
19. Her Z, *et al.* 2014. *EMBO Mol. Med.* 7:24. [PubMed](#)
20. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
21. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Lee T, *et al.* 2014. *Mol Biol Cell.* 25:583. [PubMed](#)
2. Hernández-Santana YE, *et al.* 2020. *Life Sci Alliance.* 3:00. [PubMed](#)
3. D'Alessandro G, *et al.* 2020. *Eur J Immunol.* 50:705. [PubMed](#)
4. DeSouza-Vieira T, *et al.* 2020. *Cell Rep.* 33:108317. [PubMed](#)
5. Bowling S, *et al.* 2020. *Cell.* 181(6):1410-1422.e27. [PubMed](#)
6. Combes F, *et al.* 2018. *Neoplasia.* 20:848. [PubMed](#)
7. de la Rosa X, *et al.* 2018. *Am J Pathol.* 188:950. [PubMed](#)
8. Ramakrishna C, *et al.* 2019. *Nat Commun.* 10:2153. [PubMed](#)
9. Sierro F, *et al.* 2017. *Immunity.* 47:374. [PubMed](#)
10. Yu X, *et al.* 2020. *Nat Commun.* 11:1110. [PubMed](#)
11. Guo H, *et al.* 2020. *Curr Protoc Immunol.* 131:e107. [PubMed](#)
12. Liang J, *et al.* 2021. *Cancer Manag Res.* 13:6977. [PubMed](#)
13. Zhao D, *et al.* 2021. *Innate Immun.* 27:533. [PubMed](#)
14. Zhou R, *et al.* 2022. *EBioMedicine.* 75:103762. [PubMed](#)
15. Volmari A, *et al.* 2021. *Hepato Comm.* 5:2104. [PubMed](#)
16. Da Mesquita S, *et al.* 2021. *Nature.* 593:255. [PubMed](#)
17. Cai B, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 6526 - 6531. [PubMed](#)
18. Kozik J, *et al.* 2016. *Sci Rep.* 6:28556. [PubMed](#)
19. Herz J, *et al.* 2015. *J Exp Med.* 212: 1153 - 1169. [PubMed](#)
20. Jackson A, *et al.* 2014. *J Leukoc Biol.* 92:609. [PubMed](#)
21. Jung J, *et al.* 2019. *Cell Host Microbe.* 25:513. [PubMed](#)
22. Fachi JL *et al.* 2019. *Cell reports.* 27(3):750-761. [PubMed](#)
23. Alissafi T, *et al.* 2018. *J Clin Invest.* 128:3840. [PubMed](#)
24. Iwamoto H *et al.* 2018. *Cell metabolism.* 28(1):104-117. [PubMed](#)
25. Gawish R, *et al.* 2022. *Elife.* 11:.. [PubMed](#)
26. Li X, *et al.* 2022. *Nat Commun.* 13:2794. [PubMed](#)
27. He J, *et al.* 2022. *Front Immunol.* 12:760138. [PubMed](#)
28. Ancey PB, *et al.* 2021. *Cancer Res.* 81:2345. [PubMed](#)
29. Machata S, *et al.* 2021. *Front Immunol.* 11:565869. [PubMed](#)
30. Tang L, *et al.* 2021. *Oncol Lett.* 22:605. [PubMed](#)
31. Ajendra J, *et al.* 2016. *Sci Rep.* 6:39648. [PubMed](#)
32. Bottek J, *et al.* 2020. *Mucosal Immunol.* 1.029166667. [PubMed](#)
33. Sharma K, *et al.* 2021. *Cell Reports.* 36(3):109351. [PubMed](#)
34. Zhang Y, *et al.* 2018. *Sci Rep.* 8:5994. [PubMed](#)
35. Kenichi Shimada *et al.* 2018. *Immunity.* 49(5):873-885. [PubMed](#)
36. Zhang K, *et al.* 2018. *PLoS Pathog.* 14:e1006925. [PubMed](#)
37. Delás MJ, *et al.* 2019. *Cell Rep.* 27:719. [PubMed](#)
38. Putnam NE, *et al.* 2019. *PLoS Pathog.* 15:e1007744. [PubMed](#)
39. Hanhai Z, *et al.* 2021. *Aging (Albany NY).* 13:13108. [PubMed](#)
40. Choi YY, *et al.* 2021. *Cell Death Dis.* 12:826. [PubMed](#)
41. Acharya N, *et al.* 2020. *Immunity.* 53(3):658-671.e6. [PubMed](#)
42. Clement M, *et al.* 2016. *PLoS Pathog.* 12:e1006050. [PubMed](#)
43. Montufar-Solis D, Klein J 2016. *PLoS One.* 11: 014611. [PubMed](#)
44. Sun P, *et al.* 2015. *J Hepatol.* [PubMed](#)
45. Okada M, *et al.* 2014. *J Biol Chem.* 289:32926. [PubMed](#)
46. Lechner AJ *et al.* 2017. *Cell stem cell.* 21(1):120-134. [PubMed](#)
47. Ishii T, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-12513-1. [PubMed](#)
48. Xie D, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0181454. [PubMed](#)
49. Muhammad W, *et al.* 2022. *Acta Biomater.* 148:258. [PubMed](#)
50. Rogic A, *et al.* 2021. *Nat Commun.* 12:6889. [PubMed](#)
51. Harding M, *et al.* 2014. *PLoS Pathog.* 10:1004379. [PubMed](#)
52. Morales D, *et al.* 2015. *J Virol.* 89:337. [PubMed](#)
53. Lin T, *et al.* 2015. *PLoS One.* 10: e0138335. [PubMed](#)
54. Iwata H, *et al.* 2016. *Nat Commun.* 7:12849. [PubMed](#)
55. Yeo WS, *et al.* 2020. *J Bacteriol.* 202:00:00. [PubMed](#)
56. Webster HC, *et al.* 2020. *J Immunol Methods.* 112702:477. [PubMed](#)
57. Pham THM, *et al.* 2020. *Cell Host & Microbe.* 27(1):54-67.e5. [PubMed](#)
58. Go DM, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:715. [PubMed](#)
59. Bae SH, *et al.* 2021. *Theranostics.* 11:2522. [PubMed](#)
60. Zhou HF, *et al.* 2022. *Front Pharmacol.* 13:778755. [PubMed](#)
61. Helm M, *et al.* 2022. *Life (Basel).* 12:.. [PubMed](#)
62. Dolgova EV, *et al.* 2022. *Int J Mol Sci.* 23:.. [PubMed](#)
63. Papafragkos I, *et al.* 2022. *Front Immunol.* 13:889075. [PubMed](#)
64. Lemon J, *et al.* 2015. *Infect Immun.* 83: 3204-3212. [PubMed](#)
65. Zhou Z, *et al.* 2019. *Oxid Med Cell Longev.* 2019:1209307. [PubMed](#)
66. Mastandrea I, *et al.* 2022. *STAR Protoc.* 3:101106. [PubMed](#)
67. Ma M, *et al.* 2021. *Front Immunol.* 12:718779. [PubMed](#)

68. Zhang Z, *et al.* 2021. *Oncoimmunology*. 10:1912472. [PubMed](#)
69. Metzger D, *et al.* 2015. *J Infect Dis*. 212: 445-452. [PubMed](#)
70. Winkler MJ, *et al.* 2020. *Basic Res Cardiol*. 115:67. [PubMed](#)
71. Ku MW, *et al.* 2020. *Cell Host Microbe*. 29(2):236-249.e6. [PubMed](#)
72. Ratitong B, *et al.* 2021. *Cell Reports*. 35(7):109139. [PubMed](#)
73. Müller A, *et al.* 2020. *J Clin Invest*. 5765:130. [PubMed](#)
74. Fujita Y *et al.* 2018. *Cell reports*. 24(12):3296-3311 . [PubMed](#)
75. Schaffert A, *et al.* 2020. *Front Immunol*. 10:3024. [PubMed](#)
76. Galvão I, *et al.* 2018. *Front Immunol*. 9:142. [PubMed](#)
77. Shin SH, *et al.* 2022. *Front Cell Neurosci*. 16:844480. [PubMed](#)
78. Zhang J, *et al.* 2022. *iScience*. 25:104963. [PubMed](#)
79. Qiu Z, *et al.* 2016. *Sci Rep*. 6:31936. [PubMed](#)
80. Kojo K, *et al.* 2016. *Sci Rep*. 6:29650. [PubMed](#)
81. Hegde S, *et al.* 2020. *Cancer Cell*. 37(3):289-307. [PubMed](#)
82. Al Mamun A, *et al.* 2019. *Neurochem Int*. 127:148. [PubMed](#)
83. Deng Z, *et al.* 2017. *Oncogene*. 36:639. [PubMed](#)
84. Varol D *et al.* 2017. *Immunity*. 46(6):1030-1044 . [PubMed](#)
85. McLaughlin PA *et al.* 2019. *PLoS Pathog*. 15(7):e1007847 . [PubMed](#)
86. Linde N, *et al.* 2018. *Nat Commun*. 9:21. [PubMed](#)
87. Soto-Díaz K, *et al.* 2021. *Front Immunol*. 12:734349. [PubMed](#)
88. El-Zaatari M, *et al.* 2014. *J Immunol*. 193:807. [PubMed](#)
89. Hulsmans M *et al.* 2017. *Cell*. 169(3):510-522 . [PubMed](#)
90. Si Y, *et al.* 2018. *J Control Release*. 282:120. [PubMed](#)
91. Du Y, *et al.* 2022. *Nat Commun*. 13:231. [PubMed](#)
92. Catani J, *et al.* 2016. *Transl Oncol*. 9:565-574. [PubMed](#)
93. Markman JL, *et al.* 2020. *Nat Commun*. 11:1613. [PubMed](#)
94. Wheeler MA, *et al.* 2019. *Cell*. 176:581. [PubMed](#)
95. Steuerma Y *et al.* 2018. *Cell systems*. 6(6):679-691 . [PubMed](#)
96. Zhou Z, *et al.* 2022. *Life (Basel)*. 12:. [PubMed](#)
97. Yong L, *et al.* 2022. *Nat Commun*. 13:4255. [PubMed](#)
98. Coquery C, *et al.* 2014. *PLoS One*. 9:102284. [PubMed](#)
99. Umeshappa CS, *et al.* 2021. *Cell Reports*. 34(13):108919. [PubMed](#)
100. Abe M, *et al.* 2020. *Clin Exp Immunol*. 303:199. [PubMed](#)
101. Zhou G, *et al.* 2019. *FASEB J*. 33:11396. [PubMed](#)
102. Su M, *et al.* 2022. *Nat Cardiovasc Res*. 1:732. [PubMed](#)
103. Frenis K, *et al.* 2021. *Basic Res Cardiol*. 31:116. [PubMed](#)
104. Unudurthi SD, *et al.* 2020. *Life Sci*. 117440:247. [PubMed](#)
105. Finsterbusch M, *et al.* 2014. *J Exp Med*. 211:1307. [PubMed](#)
106. Vergadi E, *et al.* 2014. *J Immunol*. 192:394. [PubMed](#)
107. Kim Y, *et al.* 2012. *J Immunol*. 188:4226. [PubMed](#)
108. Yamada KJ, *et al.* 2020. *PLoS Pathog*. 16:e1008354. [PubMed](#)
109. Rynkiewicz NK, *et al.* 2020. *Sci Signal*. 13:. [PubMed](#)
110. Gopinath A, *et al.* 2022. *NPJ Parkinsons Dis*. 8:72. [PubMed](#)
111. Sanmarco LM, *et al.* 2021. *Nature*. 590:473. [PubMed](#)
112. Daneshmandi S, *et al.* 2021. *Elife*. 10:. [PubMed](#)
113. Tapia-Abellán A, *et al.* 2021. *Sci Adv*. 7:eabf4468. [PubMed](#)
114. Jiang Y, *et al.* 2021. *Cell Death Differ*. 28:3009. [PubMed](#)
115. Uematsu T, *et al.* 2016. *Sci Rep*. 6:37815. [PubMed](#)
116. Takesue S, *et al.* 2020. *Int J Oncol*. 56:596. [PubMed](#)
117. Kimura H, *et al.* 2019. *Sci Rep*. 9:5887. [PubMed](#)
118. Hsu BE *et al.* 2019. *Cell Rep*. 27(13):3902-3915 . [PubMed](#)
119. Su W *et al.* 2019. *Cancer Cell*. 36(2):139-155 . [PubMed](#)
120. Bronisz-Budzynska I, *et al.* 2019. *Skelet Muscle*. 9:22. [PubMed](#)
121. Gamrekashvili J, *et al.* 2021. *Bio Protoc*. 11:e4007. [PubMed](#)
122. Takizawa S, *et al.* 2022. *Mol Med*. 28:91. [PubMed](#)
123. Ryan NM, *et al.* 2022. *Front Immunol*. 13:932742. [PubMed](#)
124. Wang G, *et al.* 2021. *Cell Host Microbe*. 29(5):777-791.e6. [PubMed](#)
125. Swanson P, *et al.* 2016. *PLoS Pathog*. 12:e1006022. [PubMed](#)
126. Kim M, *et al.* 2018. *Immunity*. 49:151. [PubMed](#)
127. Petkevicius K, *et al.* 2019. *Elife*. 8:e47990. [PubMed](#)
128. Baomei Wang *et al.* 2019. *Cell reports*. 26(6):1614-1626 . [PubMed](#)
129. Matsumura T, *et al.* 2022. *Nat Commun*. 13:7064. [PubMed](#)
130. Murray MP, *et al.* 2022. *Cell Rep*. 38:110209. [PubMed](#)
131. Wang W, *et al.* 2021. *J Am Heart Assoc*. 10:e019142. [PubMed](#)
132. Penke LR, *et al.* 2020. *Life Sci Alliance*. 3:. [PubMed](#)
133. Liu Y, *et al.* 2015. *BioMed Res Int*. 2015 563425. [PubMed](#)
134. Jiang L, *et al.* 2020. *Cell*. 183(5):1219-1233.e18. [PubMed](#)
135. Onai N, *et al.* 2020. *Int J Mol Sci*. :22. [PubMed](#)
136. Wang T *et al.* 2018. *Immunity*. 49(3):504-514 . [PubMed](#)
137. Laban H, *et al.* 2018. *J Cell Biol*. 217:1503. [PubMed](#)
138. Chiang N, *et al.* 2019. *J Clin Invest*. 129:5294. [PubMed](#)
139. Eislmayr K, *et al.* 2022. *Sci Adv*. 8:eabj7293. [PubMed](#)
140. Unsinger J, *et al.* 2021. *J Leukoc Biol*. 109:697. [PubMed](#)
141. Vaibhav K, *et al.* 2020. *Sci Adv*. 6:eaax8847. [PubMed](#)
142. Huang W, *et al.* 2016. *Cell Death Differ*. 10.1038/cdd.2016.115. [PubMed](#)
143. Buerfent BC, *et al.* 2019. *GMS Infect Dis*. 7:Doc04. [PubMed](#)
144. Grayczyk JP *et al.* 2017. *Cell host & microbe*. 22(5):678-687 . [PubMed](#)
145. Clemente-Casares X, *et al.* 2017. *Immunity*. 47:974. [PubMed](#)
146. Zhu YP *et al.* 2018. *Cell reports*. 24(9):2329-2341 . [PubMed](#)
147. Sadhu S, *et al.* 2021. *J Immunol*. 207:1812. [PubMed](#)

148. Rao L, *et al.* 2020. *Nat Commun.* 11:4909. [PubMed](#)
149. Ding R, *et al.* 2022. *J Neuroinflammation.* 19:137. [PubMed](#)
150. Zhang W, *et al.* 2021. *Front Immunol.* 12:768435. [PubMed](#)
151. Zheng Y, *et al.* 2022. *J Immunol.* 208:501. [PubMed](#)
152. Issah Y, *et al.* 2021. *Elife.* 10:. [PubMed](#)
153. Kiss M, *et al.* 2020. *Cancer Immunol Res.* 9:309. [PubMed](#)
154. Kimura T, *et al.* 2014. *Int Immunol.* 26:697. [PubMed](#)
155. Fujimura N, *et al.* 2016. *Sci Rep.* 5:11664. [PubMed](#)
156. Hu R, *et al.* 2015. *J Immunol.* 195: 4802 - 4809. [PubMed](#)
157. Zhang T, *et al.* 2020. *JCI Insight.* 5:00. [PubMed](#)
158. Huang WC, *et al.* 2020. *Adv Mater.* 32:e2005637. [PubMed](#)
159. Matsumoto M, *et al.* 2021. *Cell Host Microbe.* 29(6):930-940.e4. [PubMed](#)
160. Porrello A, *et al.* 2018. *Nat Commun.* 9:1988. [PubMed](#)
161. Kong XF, *et al.* 2018. *Nat Immunol.* 19:973. [PubMed](#)
162. Weckbach LT, *et al.* 2019. *J Exp Med.* 216:350. [PubMed](#)
163. Subramaniam N, *et al.* 2021. *Blood Adv.* 5:1259. [PubMed](#)
164. Li Y, *et al.* 2022. *Theranostics.* 12:5364. [PubMed](#)
165. Zhai T, *et al.* 2020. *Clin Exp Pharmacol Physiol.* 47:677. [PubMed](#)
166. Xu C, *et al.* 2021. *Cell Reports.* 35(11):109235. [PubMed](#)
167. Martins R, *et al.* 2016. *Nat Immunol.* 17:1361-1372. [PubMed](#)
168. Guo H, *et al.* 2016. *J Immunol.* 196: 2300 - 2308. [PubMed](#)
169. Li Y, *et al.* 2020. *Theranostics.* 10:11376. [PubMed](#)
170. Nguyen HX *et al.* 2017. *J Neurosci.* 37(38):9269-9287 . [PubMed](#)
171. Moraes JA, *et al.* 2018. *J Innate Immun.* 11:330. [PubMed](#)
172. Zhao Z, *et al.* 2019. *J Immunol Res.* 2019:9561350. [PubMed](#)
173. Winter C, *et al.* 2018. *Cell Metab.* 28:175. [PubMed](#)
174. Hirota K *et al.* 2018. *Immunity.* 48(6):1220-1232 . [PubMed](#)
175. Ishihara J, *et al.* 2018. *Nat Commun.* 9:2163. [PubMed](#)
176. Bozoglu T, *et al.* 2022. *Adv Sci (Weinh).* 9:e2103867. [PubMed](#)
177. Chen YL, *et al.* 2022. *Front Neurosci.* 16:876582. [PubMed](#)
178. Hou Y, *et al.* 2013. *J Nutr Biochem.* 24:1555. [PubMed](#)
179. Zhang S, *et al.* 2016. *PLoS Pathog.* 12: 1005617. [PubMed](#)
180. Wang J, *et al.* 2020. *Cell.* 183(7):1867-1883.e26. [PubMed](#)
181. Heyde A, *et al.* 2021. *Cell.* 184(5):1348-1361.e22. [PubMed](#)
182. Wang X, *et al.* 2021. *Immunity.* 54(6):1123-1136.e8. [PubMed](#)
183. Schuran FA, *et al.* 2020. *Cell Mol Gastroenterol Hepatol.* . [PubMed](#)
184. Wheeler MA, *et al.* 2020. *Nature.* 578:593. [PubMed](#)
185. Wang C, *et al.* 2020. *Mucosal Immunol.* 13:22. [PubMed](#)
186. Weng JH, *et al.* 2021. *Nat Metab.* 3:513. [PubMed](#)
187. Shin SH, *et al.* 2022. *Clin Exp Otorhinolaryngol.* . [PubMed](#)
188. Zha ZX, *et al.* 2022. *Acta Pharmacol Sin.* . [PubMed](#)
189. Jia J, *et al.* 2022. *Nat Commun.* 13:6804. [PubMed](#)
190. Zhang B, *et al.* 2021. *Front Neurol.* 607370:12. [PubMed](#)
191. Uematsu T, *et al.* 2015. *Sci Rep.* 5: 17577. [PubMed](#)
192. Rodgers M, *et al.* 2014. *J Exp Med.* 211:1333. [PubMed](#)
193. Hellmann J, *et al.* 2013. *J Immunol.* 191:1383. [PubMed](#)
194. Ma Y, *et al.* 2020. *Front Immunol.* 11:586685. [PubMed](#)
195. Pessoa Rodrigues C, *et al.* 2020. *Sci Adv.* 6:eaaz4815. [PubMed](#)
196. Thomson CA, *et al.* 2018. *J Immunol.* 201:215. [PubMed](#)
197. Ribechini E, *et al.* 2017. *Blood Adv.* 0.699305556. [PubMed](#)
198. Qu J, *et al.* 2021. *Int J Biol Sci.* 17:2756. [PubMed](#)

**RRID** AB\_1186104 (BioLegend Cat. No. 127607)  
 AB\_1186099 (BioLegend Cat. No. 127608)

## Antigen Details

---

<b>Structure</b>	A 21-35 kD GPI-anchored membrane protein
<b>Distribution</b>	Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
<b>Cell Type</b>	Granulocytes, Macrophages, Monocytes
<b>Biology Area</b>	Immunology, Innate Immunity
<b>Antigen References</b>	Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2399.
<b>Gene ID</b>	<a href="#">546644</a>


## Related Protocols

---

## Other Formats

Alexa Fluor® 594 anti-mouse Ly-6G, Purified anti-mouse Ly-6G, Biotin anti-mouse Ly-6G, FITC anti-mouse Ly-6G, PE anti-mouse Ly-6G, Alexa Fluor® 647 anti-mouse Ly-6G, Pacific Blue™ anti-mouse Ly-6G, APC anti-mouse Ly-6G, PerCP/Cyanine5.5 anti-mouse Ly-6G, PE/Cyanine7 anti-mouse Ly-6G, Alexa Fluor® 700 anti-mouse Ly-6G, APC/Cyanine7 anti-mouse Ly-6G, Alexa Fluor® 488 anti-mouse Ly-6G, Brilliant Violet 421™ anti-mouse Ly-6G, Brilliant Violet 570™ anti-mouse Ly-6G, Ultra-LEAF™ Purified anti-mouse Ly-6G, Brilliant Violet 510™ anti-mouse Ly-6G, Purified anti-mouse Ly-6G (Maxpar® Ready), Brilliant Violet 650™ anti-mouse Ly-6G, Brilliant Violet 711™ anti-mouse Ly-6G, Brilliant Violet 605™ anti-mouse Ly-6G, Brilliant Violet 785™ anti-mouse Ly-6G, PE/Dazzle™ 594 anti-mouse Ly-6G, APC/Fire™ 750 anti-mouse Ly-6G, PerCP anti-mouse Ly-6G, TotalSeq™-A0015 anti-mouse Ly-6G, TotalSeq™-C0015 anti-mouse Ly-6G, TotalSeq™-B0015 anti-mouse Ly-6G, Spark Blue™ 550 anti-mouse Ly-6G, Spark NIR™ 685 anti-mouse Ly-6G, Spark YG™ 593 anti-mouse Ly-6G, APC/Fire™ 810 anti-mouse Ly-6G Antibody, PE/Cyanine5 anti-mouse Ly-6G, PE/Fire™ 810 anti-mouse Ly-6G Antibody, Spark UV™ 387 anti-mouse Ly-6G, PE/Fire™ 640 anti-mouse Ly-6G

## Product Data



C57BL/6 bone marrow cells stained with 1A8 PE (gated on myeloid cells)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587